Is the input to a GABAergic or cholinergic synapse the sole asymmetry in rabbit's retinal directional selectivity?
We examined contrast, direction of motion, and concentration dependencies of the effects of GABAergic and cholinergic antagonists, and anticholinesterases on responses to movement of On-Off directionally selective (DS) ganglion cells of the rabbit's retina. The drugs tested were curare and hexamethonium bromide (cholinergic antagonists), physostigmine (anticholinesterase), and picrotoxin (GABAergic antagonist). They all reduced the cells' directional selectivity, while maintaining their preferred-null axis. However, cholinergic antagonists did not block directional selectivity completely even at saturating concentrations. The failure to eliminate directional selectivity was probably not due to an incomplete blockade of cholinergic receptors. In a extension of a Masland and Ames (1976) experiment, saturating concentrations of antagonists blocked the effects of exogenous acetylcholine or nicotine applied during synaptic blockade. Consequently, a noncholinergic pathway may be sufficient to account for at least some directional selectivity. This putative pathway interacts with the cholinergic pathway before spike generation, since physostigmine eliminated directional selectivity at contrasts lower than those saturating responses. This elimination apparently resulted from cholinergic-induced saturation, since reduction of contrast restored directional selectivity. Under picrotoxin, directional selectivity was lost in 33% of the cells regardless of contrast. However, 47% maintained their preferred direction despite saturating concentrations of picrotoxin, and 20% reversed the preferred and null directions. Therefore, models based solely on a GABAergic implementation of Barlow and Levick's asymmetric-inhibition model or solely on a cholinergic implementation of asymmetric-excitation models are not complete models of directional selectivity in the rabbit. We propose an alternate model for this retinal property.
Grzywacz
N M
NM
Smith-Kettlewell Eye Research Institute, San Francisco, CA 94115, USA.
Tootle
J S
JS
Amthor
F R
FR
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D002802:Cholinesterases / Q000494:pharmacology; D005074:Evoked Potentials, Visual; D018756:GABA Antagonists / Q000494:pharmacology; D018738:Hexamethonium / Q000494:pharmacology; D066298:In Vitro Techniques; D009039:Motion Perception / Q000502:physiology*; D018733:Nicotinic Antagonists / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D010830:Physostigmine / Q000494:pharmacology; D010852:Picrotoxin / Q000494:pharmacology; D011817:Rabbits; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000378:metabolism*; D018079:Receptors, GABA / Q000187:drug effects / Q000378:metabolism*; D012165:Retinal Ganglion Cells / Q000187:drug effects / Q000502:physiology*; D013569:Synapses / Q000187:drug effects / Q000502:physiology*
D000109:Acetylcholine; D002800:Cholinesterase Inhibitors; D002802:Cholinesterases; D018756:GABA Antagonists; D018738:Hexamethonium; D018733:Nicotinic Antagonists; D010830:Physostigmine; D010852:Picrotoxin; D011950:Receptors, Cholinergic; D018079:Receptors, GABA